Evidence map›Paper›PMID 30223899›Full record

ReviewBiology of sex differences2018

Sex differences in ischemic heart disease and heart failure biomarkers.

Kimia Sobhani, Diana K Nieves Castro, Qin Fu, Roberta A Gottlieb, Jennifer E Van Eyk, C Noel Bairey Merz

Open access · goldAbstract readReview
In one paragraph

Review in Biology of sex differences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Sex differences research is important!Biology of sex differences · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Impact of multiple substance use on circulating ST2, a biomarker of adverse cardiac remodelling, in women.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Cyclic GMP and PKG Signaling in Heart Failure.Frontiers in pharmacology · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kimia SobhaniPathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Diana K Nieves CastroBarbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, 127 S. San Vicente Blvd, Suite A3206, Los Angeles, CA, 90048, USA.
Qin FuAdvanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Roberta A GottliebAdvanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jennifer E Van EykAdvanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
C Noel Bairey MerzBarbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, 127 S. San Vicente Blvd, Suite A3206, Los Angeles, CA, 90048, USA. Noel.BaireyMerz@cshs.org.ORCID 0000-0002-9933-5155
Cedars-Sinai Medical Center · USCedars-Sinai Smidt Heart Institute · US

Funding

Genomic and Proteomic Architecture of AtherosclerosisR01HL111362 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HERRINGTON, DAVID MCLEOD · 2012 to 2021
$17.2M
Protein Chemistry and ProteomicsP01HL112730 · NHLBI · SAN DIEGO STATE UNIVERSITY · PI VAN EYK, JENNIFER E · 2013 to 2017
$12.0M
Mitochondrial Turnover in the Human HeartR01HL132075 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI GOTTLIEB, ROBERTA A., VAN EYK, JENNIFER E · 2017 to 2020
$2.1M
NHLBI NIH HHS P01 HL112730NHLBI NIH HHS R01 HL111362NHLBI NIH HHS R01 HL132075
6 · The paper itself

Abstract

Since 1984, each year, more women than men die of ischemic heart disease (IHD) and heart failure (HF), yet more men are diagnosed. Because biomarker assessment is often the first diagnostic employed in such patients, understanding biomarker differences in men vs. women may improve female morbidity and mortality rates.Some key examples of cardiac biomarker utility based on sex include contemporary use of "unisex" troponin reference intervals under-diagnosing myocardial necrosis in women; greater use of hsCRP in the setting of acute coronary syndrome (ACS) could lead to better stratification in women; and greater use of BNP with sex-specific thresholds in ACS could also lead to more timely risk stratification in women.Accurate diagnosis, appropriate risk management, and monitoring are key in the prevention and treatment of cardiovascular diseases; however, the assessment tools used must also be useful or at least assessed for utility in both sexes. In other words, going forward, we need to evaluate sex-specific reference intervals or cutoffs for laboratory tests used to assess cardiovascular disease to help close the diagnostic gap between men and women.

Indexed as

Sex CharacteristicsAnimalsBiomarkersC-Reactive ProteinCreatine Kinase, MB FormFemaleHeart FailureHumansMaleMyocardial IschemiaNatriuretic Peptide, BrainTroponinBiomarkersC-Reactive ProteinCreatine Kinase, MB FormNatriuretic Peptide, BrainTroponinBiomarkerCardiovascularSex

Identifiers

PMID30223899
PMCPMC6142320
OpenAlexW2891415136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.